… Author links open overlay panel Rosa Polo 1 , Xabier García-Albéniz 2 3 , Carolina Terán
4 , Miguel Morales 5 , David Rial-Crestelo 6 7 , M. Angeles Garcinuño 8 , Miguel García del …

Background We investigated the efficacy of a switch to dolutegravir plus lamivudine in aviremic
individuals without evidence of persistent lamivudine resistance-associated mutations in …

Background In the ART-PRO pilot trial there were no virological failures through 48 weeks
of treatment with dolutegravir plus lamivudine in suppressed individuals with and without …

We have investigated the evolution of the neutralizing response against severe acute
respiratory syndrome coronavirus 2 (SARS-CoV-2) variants at 8 months after Pfizer-BNT162b2 …

We have measured the humoral response to messenger RNA (mRNA) vaccines in COVID‐19
naïve and convalescent individuals. Third doses of mRNA COVID‐19 vaccines induced a …

Background: We aim to investigate the infection rate, the clinical characteristics and outcomes
of COVID-19-disease in a cohort of people living with HIV in Madrid (Spain), during the …

Objectives To assess the effectiveness and tolerability of dolutegravir (DTG)/lamivudine (3TC)
among treatment-naive and virologically suppressed treatment-experienced individuals in …

Introduction: Antiretroviral treatment (ART) has led to improved control of HIV infection, giving
the opportunity of exploring therapeutic alternatives as new long-acting (LA) regimens, that …

Objectives To pinpoint factors associated with low‐level viraemia (LLV) and virological failure
(VF) in people living with HIV in the era of high‐efficacy antiretroviral treatment (ART) and …

Objective: To evaluate the progression of liver stiffness after treatment with direct antiviral
agents (DAAs), to identify predictive factors of fibrosis regression and to analyze the changes of …